Drug intelligence / Profile preview

MBI-201.0

Development stage: Unknown
Lead developer: Matrix Biomed
Modality: Small Molecules
Administration: Oral

Overview

MBI-201.0 is a tempol-based small molecule drug candidate developed by Matrix Biomed for the prevention and treatment of oral mucositis. It functions as a modulator of hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2), which are master regulators of the cellular response to hypoxia and are involved in tissue damage and inflammation. By modulating these pathways, MBI-201.0 aims to reduce the toxicities associated with radiation and chemotherapy, specifically oral mucositis in patients with head and neck cancer. The drug is currently in Phase 2 clinical development.

Other names: tempol

Targets

HIF1A (Hypoxia-inducible factor 1-alpha)EPAS1 (Hypoxia-inducible factor 2-alpha)

Beyond the preview

Go deeper on MBI-201.0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBI-201.0.

Explore the full profile